Andrew Portuguese
@aportugu.bsky.social
Assistant Professor in BMT/IMTX at Fred Hutch/University of Washington. Passionate about multiple myeloma. Views are mine.
🚨 New article in Haematologica: Myeloma patients with extramedullary disease face more severe toxicities and worse outcomes after BCMA CAR-T therapy, including more ICANS, prolonged cytopenias, more inflammation, and worse non-relapse mortality.
Read more: haematologica.org/article/view...
Read more: haematologica.org/article/view...
June 19, 2025 at 4:30 PM
🚨 New article in Haematologica: Myeloma patients with extramedullary disease face more severe toxicities and worse outcomes after BCMA CAR-T therapy, including more ICANS, prolonged cytopenias, more inflammation, and worse non-relapse mortality.
Read more: haematologica.org/article/view...
Read more: haematologica.org/article/view...
Reposted by Andrew Portuguese
Sometimes in Seattle you find your spirit animal.
June 12, 2025 at 11:39 PM
Sometimes in Seattle you find your spirit animal.
🔬 Science Spotlight: A real-world, 3-year analysis compares axi-cel & liso-cel for relapsed LBCL.
Both CAR T-cell therapies were equally effective, but liso-cel had a better safety profile, with less CRS, neurotoxicity, and need for supportive care.
🔗 www.fredhutch.org/en/news/spot...
Both CAR T-cell therapies were equally effective, but liso-cel had a better safety profile, with less CRS, neurotoxicity, and need for supportive care.
🔗 www.fredhutch.org/en/news/spot...
A tale of two T-cells: comparing liso-cel and axi-cel for treatment of refractory large B-cell lymphoma
Researchers in the Clinical Research Division analyze safety and efficacy of two CAR T-cell therapies in large B-cell lymphoma
www.fredhutch.org
May 27, 2025 at 7:56 PM
🔬 Science Spotlight: A real-world, 3-year analysis compares axi-cel & liso-cel for relapsed LBCL.
Both CAR T-cell therapies were equally effective, but liso-cel had a better safety profile, with less CRS, neurotoxicity, and need for supportive care.
🔗 www.fredhutch.org/en/news/spot...
Both CAR T-cell therapies were equally effective, but liso-cel had a better safety profile, with less CRS, neurotoxicity, and need for supportive care.
🔗 www.fredhutch.org/en/news/spot...